Skip to main content

Luminex Board Authorizes $22.75M Share Buyback

NEW YORK (GenomeWeb News) – Luminex's board of directors has authorized the company to repurchase up to the lesser of $22.75 million worth of its common stock or 650,000 shares, the firm said in a document filed today with the US Securities and Exchange Commission.

In the filing, the Austin, Texas-based firm said that it may repurchase its stock in the open market from time to time or in privately negotiated transactions.

The firm's board had authorized a share buyback program in November 2010 for $21 million.

Luminex is scheduled to release its fourth-quarter and full-year 2011 earnings on Feb. 6. As of Sept. 30, 2011, it had $65.1 million in cash and cash equivalents and $31.6 million in short-term investments.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.